Plasmodium dihydrofolate reductase is a second enzyme target for the antimalarial action of triclosan

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Bilsland, Elizabeth ^a,b   Van Vliet, Liisa ^a   Williams, Kevin ^c   Feltham, Jack ^a   Carrasco, Marta P ^d   Fotoran, Wesley L ^e   Cubillos, Eliana F G ^e   Wunderlich, Gerhard ^e   Grøtli, Morten ^d   Hollfelder, Florian ^a   Jackson, Victoria ^f   King, Ross D ^f   Oliver, Stephen G ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c ABERYSTWYTH UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; PROTEIN BINDING; TRICLOSAN;

BINDING SITE; CHEMISTRY; CONFORMATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; MOLECULAR MODEL; PLASMODIUM; STRUCTURE ACTIVITY RELATION;

ANTIMALARIALS; BINDING SITES; ENZYME ACTIVATION; FOLIC ACID ANTAGONISTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PLASMODIUM; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TRICLOSAN;

EID: 85040953233     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-19549-x     Document Type: Article

References (42)

1. Wells, T. N., van Huijsduijnen, R. H. & Van Voorhis, W. C. Malaria medicines: A glass half full Nature reviews. Drug discovery 14, 424-442 (2015).
2. Melo, G. C., et al. Expression levels of pvcrt-o and pvmdr-1 are associated with chloroquine resistance and severe Plasmodium vivax malaria in patients of the Brazilian Amazon. PLoS One 9, e105922 (2014).
3. Mikolajczak, S. A., et al. Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Cell Host Microbe 17, 526-535 (2015).
4. Miotto, O., et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature genetics 47, 226-234 (2015).
5. Fairhurst, R.M. Understanding artemisinin-resistant malaria: What a difference a year makes. Current opinion in infectious diseases (2015).
6. Chugh, M., et al. Identification and deconvolution of cross-resistance signals from antimalarial compounds using multidrugresistant Plasmodium falciparum strains. Antimicrob Agents Chemother 59, 1110-1118 (2015).
7. Dunachie, S., Hill, A. V. & Fletcher, H. A. Profiling the host response to malaria vaccination and malaria challenge. Vaccine (2015).
8. Howes, R. E., et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J 12, 418 (2013).
9. Bhargava, H. N. & Leonard, P. A. Triclosan: Applications and safety. Am J Infect Control 24, 209-218 (1996).
10. Han, J., Qiu, W., Campbell, E. C., White, J. C. & Xing, B. Nylon Bristles and Elastomers Retain Centigram Levels of Triclosan and Other Chemicals from Toothpastes: Accumulation and Uncontrolled Release. Environ Sci Technol 51, 12264-12273 (2017).
11. Surolia, N. & Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat Med 7, 167-173 (2001).
12. Singh, A. P., Surolia, N. & Surolia, A. Triclosan inhibit the growth of the late liver-stage of Plasmodium. IUBMB Life 61, 923-928 (2009).
13. Perozzo, R., et al. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J Biol Chem 277, 13106-13114 (2002).
14. Nicola, G., et al. Discovery of novel inhibitors targeting enoyl-acyl carrier protein reductase in Plasmodium falciparum by structurebased virtual screening. Biochem Biophys Res Commun 358, 686-691 (2007).
15. McLeod, R., et al. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int J Parasitol 31, 109-113 (2001).
16. Freundlich, J. S., et al. Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2-substituted triclosan derivatives. Bioorg Med Chem Lett 16, 2163-2169 (2006).
17. Frecer, V., Megnassan, E. & Miertus, S. Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier protein reductase. Eur J Med Chem 44, 3009-3019 (2009).
18. Baschong, W., et al. Triclosan is minimally effective in rodent malaria models. Nat Med 17, 33-34; author reply 34-35 (2011).
19. Anderson, J. W., et al. Novel diaryl ureas with efficacy in a mouse model of malaria. Bioorg Med Chem Lett 23, 1022-1025 (2013).
20. Freundlich, J. S., et al. X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy. J Biol Chem 282, 25436-25444 (2007).
21. Kumar, S. P., George, L. B., Jasrai, Y. T. & Pandya, H. A. Prioritization of active antimalarials using structural interaction profile of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR)-triclosan derivatives. SAR QSAR Environ Res 26, 61-77 (2015).
22. Yu, M., et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 4, 567-578 (2008).
23. Vaughan, A. M., et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 11, 506-520 (2009).
24. Bilsland, E., et al. Yeast-based automated high-throughput screens to identify anti-parasitic lead compounds. Open Biol 3, 120158 (2013).
25. Bilsland, E., et al. Functional expression of parasite drug targets and their human orthologs in yeast. PLoS Negl Trop Dis 5, e1320 (2011).
26. Keppler-Ross, S., Noffz, C. & Dean, N. A new purple fluorescent color marker for genetic studies in Saccharomyces cerevisiae and Candida albicans. Genetics 179, 705-710 (2008).
27. Sheff, M. A. & Thorn, K. S. Optimized cassettes for fluorescent protein tagging in Saccharomyces cerevisiae. Yeast 21, 661-670 (2004).
28. Williams, K., et al. Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases. J R Soc Interface 12, 20141289 (2015).
29. Witmer, K., et al. Analysis of subtelomeric virulence gene families in Plasmodium falciparum by comparative transcriptional profiling. Molec Microbiol 84, 243-259 (2012).
30. Jenkins, S., Addy, M. & Newcombe, R. Toothpastes containing 0.3% and 0.5% triclosan. I. Effects on 4-day plaque regrowth. Am J Dent 2(Spec No), 211-214 (1989).
31. Srinivasan, S., et al. Plaque triclosan concentration and antimicrobial efficacy of a new calcium carbonate toothpaste with 0.3% triclosan compared to a marketed 0.3% triclosan toothpaste. J Clin Dent 24, 68-72 (2013).
32. Hopkins, A. L. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 4, 682-690 (2008).
33. Tasdemir, D., et al. Inhibition of Plasmodium falciparum fatty acid biosynthesis: Evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem 49, 3345-3353 (2006).
34. Navarro-Peran, E., et al. The antifolate activity of tea catechins. Cancer Res 65, 2059-2064 (2005).
35. Baragana, B., et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature 522, 315-+ (2015).
36. Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical pharmacology 22, 3099-3108 (1973).
37. Fidock, D. A., Nomura, T. & Wellems, T. E. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Molecular pharmacology 54, 1140-1147 (1998).
38. Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193, 673-675 (1976).
39. Smilkstein, M., Sriwilaijaroen, N., Kelly, J. X., Wilairat, P. & Riscoe, M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48, 1803-1806 (2004).
40. Kongsaeree, P., et al. Crystal structure of dihydrofolate reductase from Plasmodium vivax: Pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci USA 102, 13046-13051 (2005).
41. Yuthavong, Y., et al. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci USA 109, 16823-16828 (2012).
42. Zhang, X., et al. Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6, 5, 6-tricyclic benzo[4, 5] thieno[2, 3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors. Bioorg Med Chem 19, 3585-3594 (2011).